Watson Pharmaceuticals, Inc.

Contact

About Watson Pharmaceuticals

Watson Pharmaceuticals, Inc. (NYSE-WPI) is a global specialty pharmaceutical company with approximately $3 billion in revenues, a broad product line and operations in well-established and emerging markets.

News about Watson Pharmaceuticals

05-Nov-2012 | business & finance

Watson Completes Actavis Acquisition

Watson Pharmaceuticals, Inc. announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world' ...

Read news

20-Jul-2012 | business & finance

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being ...

Read news

18-Nov-2009 | people

Watson Names Robert A. Stewart Senior Vice President, Global Operations

Watson Pharmaceuticals announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, ...

Read news

30-Jul-2009 | business & finance

Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit

Watson Pharmaceuticals, Inc. announced a license agreement with GeneraMedix, Inc. for the exclusive US marketing rights to a generic version of Ferrlecit ( ...

Read news

Show more news about Watson Pharmaceuticals

Get the life science industry in your inbox

Watson Pharmaceuticals, Inc.

About Watson Pharmaceuticals

News about Watson Pharmaceuticals

Watson Completes Actavis Acquisition

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

Watson Names Robert A. Stewart Senior Vice President, Global Operations

Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit

Here you will find Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc.